Abstract:The ELR-CXC chemokines play important roles in neutrophilic inflammation. We report in this study that a fully human ELR-CXC chemokine antagonist that we have generated, CXCL8((3-72))K11R/G31P (G31P), has potent anti-inflammatory effects that arise through its actions at multiple levels. G31P inhibited CXCL8-induced chemotactic responses and intracellular Ca(2+) flux in CXCR1-transfected HEK cells and neutrophils, and responses of neutrophils to CXCR2-exclusive ligands. G31P desensitized heterologous G protein-coupled receptors on neutrophils, 52-86% reducing their Ca(2+) flux and chemotactic responses to leukotriene B(4), C5a, and the bacterial tripeptide fMLP. G31P also 60-90% blocked neutrophil chemotactic responses to mediators present in 10 of 12 sputum samples from cystic fibrosis or bronchiectasis subjects with bacterial pneumonia. Moreover, whereas A549 bronchial epithelial cells (which expressed CXCR1) secreted approximately 29,000 pg/ml CXCL8 in response to in vitro endotoxin challenge, G31P reduced this response by up to 98%, presumably by interrupting an autocrine inflammatory loop. The anti-inflammatory effects of G31P extended also to reversing the antiapoptotic influence of ELR-CXC chemokines on neutrophils. That these effects were relevant in vivo was confirmed in a guinea pig model of airway endotoxemia, wherein the human form of G31P >95% blocked neutrophil infiltration into and activation within the airways, as determined by airway levels of the neutrophil primary, secondary, and tertiary granule markers myeloperoxidase, lactoferrin, and matrix metalloproteinase-9, respectively, and the epithelial cell marker matrix metalloproteinase-2. These data suggest that the beneficial effects of ELR-CXC chemokine antagonism arise through effects that occur at multiple levels, including epithelial cells, neutrophils, and alternate G protein-coupled receptors.

Study on CXCR1/CXCR2 Antagonist G31P Anti-Inflammatory Reaction Mediated by Neutrophils

Effect of adenylate cyclase antagonists andagonist in acute lung injury induced by lipopolysaccharide

ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels

PHC Inhibits Sequestration of Neutrophils and Activation of NF-kappa B in Lung Tissue of ALI Rats Induced by LPS

CXCR1/2 Antagonism with CXCL8/Interleukin-8 Analogue CXCL8(3-72)K11R/G31P Restricts Lung Cancer Growth by Inhibiting Tumor Cell Proliferation and Suppressing Angiogenesis

A CRTH2 Antagonist, CT-133, Suppresses NF-κB Signalling to Relieve Lipopolysaccharide-Induced Acute Lung Injury.

Ginsenoside Rg3 ameliorates acute exacerbation of COPD by suppressing neutrophil migration

CRTH2 Antagonist, CT‑133, Effectively Alleviates Cigarette Smoke-Induced Acute Lung Injury

Porcine CXCR1/2 antagonist CXCL8(3–72)G31P inhibits lung inflammation in LPS-challenged mice

Blockade of the CCR3 receptor reduces neutrophil recruitment to the lung during acute inflammation

Bronchoalveolar Lavage Fluid from Chronic Obstructive Pulmonary Disease Patients Increases Neutrophil Chemotaxis Measured by a Microfluidic Platform

GPR84 regulates pulmonary inflammation by modulating neutrophil functions

Inhibitory Effects of Cryptoporus Polysaccharide on Airway Constriction, Eosinophil Release, and Chemotaxis in Guinea Pigs.

Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor

Pharmacokinetics and Anti-asthmatic Potential of Non-parenterally Administered Recombinant Human Interleukin-1 Receptor Antagonist in Animal Models

Glycosaminoglycans are important mediators of neutrophilic inflammation in vivo

Unsymmetrical Phosphodiesters as GPR84 Antagonists with High Blood Exposure for the Treatment of Lung Inflammation

Pulmonary epithelial CCR3 promotes LPS-induced lung inflammation by mediating release of IL-8.

STUDY ON THE EFFECT OF PROPOLIS EXTRACTS ON ACUTE PLEURISY AND ITS MECHANISM IN RATS

Differential Therapeutic Activity of a Cargo-Free Nanoparticle in Eosinophilic and Neutrophilic Asthma Mouse Models

Effect of PD98059, a Selective MAPK3/MAPK1 Inhibitor, on Acute Lung Injury in Mice